MedTrace Logo

Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell Malignancies

NCT02006485 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2019-11-05

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and effectiveness of Ublituximab in combination with TGR-1202, with or without ibrutinib or bendamustine, in patients with advanced hematologic malignancies

Conditions

Interventions

DRUG

Ublituximab + TGR-1202

Ublituximab IV infusion TGR-1202 oral daily dose

DRUG

Ublituximab + TGR-1202 + ibrutinib

Ublituximab IV infusion TGR-1202 oral daily dose Ibrutinib oral daily dose

DRUG

Ublituximab + TGR-1202 + bendamustine

Ublituximab IV infusion TGR-1202 oral daily dose Bendamustine IV infusion

Sponsors & Collaborators

  • TG Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Nathan Fowler, MD · M.D. Anderson Cancer Center

  • Susan O'Brien, MD · University of California Irvine Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-13
Primary Completion
2019-10-31
Completion
2019-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02006485 on ClinicalTrials.gov